TICKER INTELLIGENCE
NYSE/NASDAQ: MDT
7
Active Bills
5
Gov't Contracts
50
Congressional Trades
Medtronic is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 12 active Congressional signals mentioning Medtronic, including 7 bills and 5 federal contracts. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
⚠ ⚠️ PRESIDENTIAL ACTION: Presidential Memorandum signed 7/30/2026: "Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended". This DPA action will boost investment and production in domestic critical mineral recycling and processing, likely increasing stock valuations for pure-play recovery companies and defense contractors reliant on secure rare-earth magnet supplies, while potentially raising costs for import-dependent manufacturers.
⚠ Rep. Cisneros bought $1K-$15K in CRWD on May 15, 2026 — 5 days before HR8880 (a bill boosting cybersecurity for small businesses) was introduced.
⚠ System: No overlapping signals found
⚠ System: No valid trades to analyze
⚠ System: No overlapping signals found
⚠ Rep. Julie Johnson bought $1,001 - $15,000 in RSG on 2025-12-18, 8 days before S216 ("Save Our Seas 2.0 Amendments Act") was enacted, which could create new revenue streams for waste management.
⚠ System: No suspicious timing patterns detected
⚠ Rep. Julie Johnson sold $1,001 - $15,000 in ADBE on November 3, 2025 — 2 days before the AI-Related Job Impacts Clarity Act (S3108) was introduced, a bill potentially increasing compliance burdens for tech companies.
⚠ System: No suspicious timing patterns detected
⚠ Richard Dean Dr McCormick bought $1,001 - $15,000 in BLK (BlackRock, Inc. Common Stock) on 2025-11-05, 13 days before the "ERISA Litigation Reform Act" (HR6084) was introduced, which aims to strengthen pleading standards for ERISA lawsuits.
⚠ Richard Dean Dr McCormick bought $1,001 - $15,000 in AMT on 2023-03-15, 855 days before HR4477 ("PRICE Act") was introduced, which could create new funding for infrastructure improvements.
⚠ System: No suspicious timing patterns detected
⚠ Representative Johnson sold $1,001 - $15,000 in APD on 2025-08-14, 20 days before the 'Stop Chinese Fentanyl Act of 2025' (HR747) was introduced. This bill expands sanctions on Chinese entities involved in opioid and precursor production.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Rob Bresnahan bought $1,001 - $15,000 in CAT on 2025-05-15 — 1 day before Kiewit Infrastructure West Co. was awarded a $218M Department of the Interior Contract.
⚠ System: No suspicious timing patterns detected
⚠ Rob Bresnahan sold $1,001 - $15,000 in FDX on 2025-04-08 — 1 day before the "Protecting Employees and Retirees in Business Bankruptcies Act of 2025" (S1381) was introduced, a bill aiming to increase corporate liability in bankruptcies.
⚠ George Whitesides sold $100K-$250K of Home Depot (HD) on 2025-03-24, 3 days before the 'Revitalizing Downtowns and Main Streets Act' (HR2410) was introduced, which proposes an investment tax credit for converting non-residential buildings.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Randall sold $1K-$15K in AMGN (Amgen) on Jan 6, 2025 — 3 days before the Skinny Labels, Big Savings Act (S43) was introduced, a bill that creates a safe harbor for generic drug manufacturers and is bearish for branded drug makers.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ Rep. Moskowitz bought $1K-$15K in MSFT on Sep 1, 2023 — 335 days before a $150M SSA contract to Four Points Technology for AWS Connect services, which aligns with Microsoft's cloud ecosystem.
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No suspicious timing patterns detected
⚠ System: No valid trades to analyze
This $929 million contract to TriWest Healthcare Alliance, a major VA healthcare provider, signals continued federal investment in veteran health services, potentially benefiting publicly traded managed care organizations that serve similar populations or act as subcontractors.
This $23.2 million Department of Veterans Affairs contract for expanding and renovating the Tucson Emergency Department is awarded to a private joint venture, CAPEX & D SQUARE. While not directly impacting a public company, it signals continued federal investment in healthcare infrastructure, benefiting publicly traded hospital operators and construction firms in the long term.
This $820 million contract to TriWest Healthcare Alliance, a private entity, for VA healthcare services will indirectly benefit publicly traded healthcare providers and insurers. While not directly impacting a public company's revenue, it signals continued federal spending in the healthcare sector, particularly for veteran services.
This $16.5 million contract for medical staffing services to NORTH EAST SOUTH WEST HEALTHCARE SOLUTIONS, LLC, a private entity, suggests a stable demand for healthcare personnel within federal agencies. Publicly traded healthcare staffing companies like AMN Healthcare Services ($AMN) and Robert Half International ($RHI) may see a slight positive sentiment due to sustained government spending in this sector, though direct revenue impact is negligible.
This $16.9M contract to NATIONWIDE HEALTHCARE SOLUTIONS, LLC for clinical support services is a moderate win for the private entity, but it highlights ongoing demand in the healthcare staffing and services sector, potentially benefiting publicly traded competitors.
The HEAR Act of 2025 is an early-stage, unfunded bill with no Senate companion, no committee hearing, and no markup. It proposes Medicare coverage for hearing aids, which would expand the total addressable market for hearing health, but no publicly traded pure-play hearing aid companies are represented in the provided ticker list. The bill has zero legislative momentum and zero appropriated funding, making it a non-event for current market pricing.
HR3826 expands Medicare coverage of diabetes self-management training, removing hour limits and testing virtual delivery. This structurally increases the diagnostically engaged Medicare beneficiary pool, directly benefiting CGM makers ($DXCM, $ABT) and insulin pump manufacturers ($MDT). The bill is early-stage but has a Senate companion and bipartisan sponsorship, and current stock prices for all three tickers are near 52-week lows, potentially discounting this structural catalyst.
→ Medicare beneficiaries with diabetes receive additional DSMT hours (initial 10 hours until used, plus 2 hours per year) without the previous cap; the virtual pilot broadens access. Expanded training utilization correlates with increased insulin pump therapy adoption, particularly for patients new to intensive insulin management.
The Stop Corporate Inversions Act of 2026 (HR7493) is a single-sponsor bill in early committee stage with no near-term market impact. However, Medtronic ($MDT) faces direct structural risk from this bill's retroactive provisions. $MDT is already down 8.17% over 30 days and trading at $79.57, near its 52-week low of $78.91, reflecting broader sector weakness amplified by this legislative overhang.
→ Medtronic would be treated as a U.S. domestic corporation for all federal tax purposes, subjecting all of its global income to U.S. corporate income tax (currently 21%, potentially higher under future law) rather than Ireland's 12.5% rate, eliminating the tax benefit of the inversion.
Ellie's Law (HR2678) is an early-stage authorization bill directing NINDS to research unruptured intracranial aneurysms. It authorizes zero dollars, has no funding appropriation, and has only been referred to committee. Market impact is negligible in the near term for device and research tool providers like MDT, TMO, ILMN, and DGX, as no actual spending exists and the legislative path is years from completion.
→ NINDS will increase grant funding for research projects studying aneurysm treatments and devices, potentially leading to new clinical protocols and expanded reimbursement pathways.
The Stop Corporate Inversions Act (S3847) would retroactively tax inverted companies as domestic corporations, directly hitting MDT, PRGO, and ALLE with $40M to $1.2B in annual tax increases. Market prices already discount this risk: all three are near 52-week lows. The bill is early-stage but has a companion in the House, indicating legislative momentum. Investors holding these names face binary tax-expense risk with limited upside until the bill's path clarifies.
→ Medtronic would owe U.S. corporate income tax on its worldwide earnings instead of only on U.S.-sourced income, increasing its effective tax rate from ~15% to the U.S. statutory rate of 21%
HR5343 would force Medicare to provide immediate 4-year coverage for FDA breakthrough devices, directly benefiting large medical device manufacturers by eliminating the current 1-3 year coverage lag. The bill passed the Ways & Means committee 37-3 but awaits floor action. Despite bearish recent price action (MDT -8.2%, ABT -11%, BDX -7.3% in 30 days), this bill represents a structural catalyst for device revenue acceleration.
→ CMS must cover breakthrough devices during a 4-year transitional period starting at FDA clearance, eliminating the current ad-hoc process that delays coverage 1-3 years post-approval.
The PREEMIE Reauthorization Act of 2025 is an early-stage Senate bill that extends federal preterm birth research programs through FY2029 and mandates a National Academies study. It does not authorize or appropriate specific dollar amounts, and it is still in committee with no market-moving mechanism for publicly traded companies.
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →